Compare PHOS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHOS | ANTX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.3M | 172.9M |
| IPO Year | 2010 | 2022 |
| Metric | PHOS | ANTX |
|---|---|---|
| Price | $10.84 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 30.2K | ★ 236.2K |
| Earning Date | 11-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.46 | $1.00 |
| 52 Week High | $21.30 | $7.19 |
| Indicator | PHOS | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 49.94 |
| Support Level | N/A | $3.89 |
| Resistance Level | $13.37 | $5.11 |
| Average True Range (ATR) | 0.98 | 0.39 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 1.34 | 45.83 |
First Phosphate Corp owns and is developing igneous rock phosphate mineral properties in the Saguenay Region of Quebec for the production of phosphoric acid for the production of cathode active material for use in lithium iron phosphate (LPF) batteries for the electric vehicle industry.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.